BiotechTube

carfilzomib + Lenalidomide + Dexamethasone + Melphalan

Phase 2Active
0 watching 0 views this week⚡ Active
51
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Smoldering Multiple Myeloma

Conditions

Smoldering Multiple Myeloma

Trial Timeline

May 1, 2015 → Jun 1, 2027

NCT ID
NCT02415413

About carfilzomib + Lenalidomide + Dexamethasone + Melphalan

carfilzomib + Lenalidomide + Dexamethasone + Melphalan is a phase 2 stage product being developed by Amgen for Smoldering Multiple Myeloma. The current trial status is active. This product is registered under clinical trial identifier NCT02415413. Target conditions include Smoldering Multiple Myeloma.

Hype Score Breakdown

Clinical
17
Activity
12
Company
9
Novelty
5
Community
5

Clinical Trials (1)

NCT IDPhaseStatus
NCT02415413Phase 2Active

Competing Products

13 competing products in Smoldering Multiple Myeloma

See all competitors
ProductCompanyStageHype Score
Elotuzumab (BMS-901608; HuLuc63)AbbViePhase 2
52
BHQ880NovartisPhase 2
52
DenosumabAmgenPhase 2
51
Carfilzomib + Lenalidomide + Daratumumab + DexamethasoneAmgenPhase 2
51
ElranatamabPfizerPhase 2
51
Nivolumab + Lenalidomide + DexamethasoneBristol Myers SquibbPhase 2
51
Elotuzumab + Lenalidomide + DexamethasoneBristol Myers SquibbPhase 2
51
Dexamethasone + Iberdomide HydrochlorideBristol Myers SquibbPhase 2
51
LinvoseltamabRegeneron PharmaceuticalsPhase 2
51
Linvoseltamab + DaratumumabRegeneron PharmaceuticalsPhase 3
76
SelinexorKaryopharm TherapeuticsPhase 2
44
IPH2101Innate PharmaPhase 2
44
PD-L1 peptideIO BiotechPhase 2
44

Other Products from Amgen

Aranesp®Approved
84
PanitumumabApproved
84
EvolocumabApproved
84
Prolia®Approved
84
EvolocumabApproved
84